(3,4-dihydro-2H-quinolin-1-yl)-[2-(3-trifluoromethyl-phenoxy)-pyridin-3-yl]-methanone | 1224638-09-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3,4-dihydro-2H-quinolin-1-yl)-[2-(3-trifluoromethyl-phenoxy)-pyridin-3-yl]-methanone
• 英文别名: (3,4-dihydro-2H-quinolin-1-yl)-[2-(3-trifluoromethylphenoxy)pyridin-3-yl]methanone；3,4-dihydro-2H-quinolin-1-yl-[2-[3-(trifluoromethyl)phenoxy]pyridin-3-yl]methanone
• CAS: 1224638-09-8
• 化学式: C₂₂H₁₇F₃N₂O₂
• 分子量: 398.384
• InChiKey: ARQDIVACZSGTEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1,2,3,4-四氢喹啉 、 2-[3-(三氟甲基)苯氧基]烟酸 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 以56%的产率得到(3,4-dihydro-2H-quinolin-1-yl)-[2-(3-trifluoromethyl-phenoxy)-pyridin-3-yl]-methanone
  参考文献：
  名称：

  NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES

  摘要：

  这项发明涉及公式的新型苯基酰胺或吡啶基酰胺衍生物 其中A1、A2、B1、B2和R1到R11如描述和索赔中所定义，以及其药学上可接受的盐。这些化合物是GPBAR1激动剂，可用作治疗诸如2型糖尿病等疾病的药物。

  公开号：

  US20100105906A1

文献信息

• Substituted pyridines as GPBAR1 agonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US08309734B2

  公开（公告）日：2012-11-13

  This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

  本发明涉及新型苯基酰胺或吡啶基酰胺衍生物，其化学式如下： 其中A1、A2、B1、B2和R1至R11在说明书和权利要求书中定义，以及其药学上可接受的盐。这些化合物是GPBAR1激动剂，可用作治疗2型糖尿病等疾病的药物。
• NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2356094A1

  公开（公告）日：2011-08-17
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS
  申请人：Viking Therapeutics, Inc.

  公开号：US20220016136A1

  公开（公告）日：2022-01-20

  The present disclosure is directed toward the use of thyroid receptor agonists of pharmaceutically acceptable salts thereof, in combination with a second pharmaceutical agent for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
• US8309734B2
  申请人：——

  公开号：US8309734B2

  公开（公告）日：2012-11-13
• [EN] NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS<br/>[FR] NOUVEAUX DÉRIVÉS D'AMIDES PHÉNYLIQUES OU D'AMIDES PYRIDYLIQUES ET LEUR UTILISATION EN TANT AGONISTES DE GPBAR1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010049302A1

  公开（公告）日：2010-05-06

  This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula (I) wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.